Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies by Nayar, Utthara, Cohen, Ofir, Kapstad, Christian, Cuoco, Michael S., Waks, Adrienne G., Wander, Seth A., Painter, Corrie, Freeman, Samuel, Persky, Nicole S., Marini, Lori, Helvie, Karla, Oliver, Nelly, Rozenblatt-Rosen, Orit, Ma, Cynthia X., Regev, Aviv, Winer, Eric P., Lin, Nancy U., Wagle, Nikhil

Get full text